Insider Selling: NantKwest, Inc. (NK) Director Sells 39,604 Shares of Stock
NantKwest, Inc. (NASDAQ:NK) Director Steve Gorlin sold 39,604 shares of the stock in a transaction that occurred on Wednesday, September 13th. The shares were sold at an average price of $5.93, for a total transaction of $234,851.72. Following the completion of the transaction, the director now directly owns 246,280 shares of the company’s stock, valued at approximately $1,460,440.40. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.
Steve Gorlin also recently made the following trade(s):
- On Tuesday, September 12th, Steve Gorlin sold 103,841 shares of NantKwest stock. The shares were sold at an average price of $6.04, for a total transaction of $627,199.64.
- On Tuesday, June 20th, Steve Gorlin sold 40,000 shares of NantKwest stock. The shares were sold at an average price of $7.78, for a total transaction of $311,200.00.
NantKwest, Inc. (NASDAQ NK) traded down 0.34% during trading on Wednesday, hitting $5.90. 139,580 shares of the stock traded hands. The stock’s market cap is $468.70 million. The company has a 50-day moving average price of $5.95 and a 200-day moving average price of $5.06. NantKwest, Inc. has a 12 month low of $4.35 and a 12 month high of $9.60.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by Daily Political and is the property of of Daily Political. If you are reading this piece of content on another domain, it was stolen and republished in violation of international trademark and copyright laws. The original version of this piece of content can be accessed at https://www.dailypolitical.com/2017/09/13/insider-selling-nantkwest-inc-nk-director-sells-39604-shares-of-stock.html.
NK has been the subject of several analyst reports. Citigroup Inc. set a $3.00 price target on shares of NantKwest and gave the company a “sell” rating in a research note on Monday, August 14th. Zacks Investment Research raised shares of NantKwest from a “hold” rating to a “buy” rating and set a $4.50 price target for the company in a research note on Tuesday, May 16th. BidaskClub downgraded shares of NantKwest from a “hold” rating to a “sell” rating in a research note on Tuesday, August 8th. Finally, ValuEngine raised shares of NantKwest from a “strong sell” rating to a “sell” rating in a research note on Wednesday, June 14th. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and one has issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $5.94.
Institutional investors and hedge funds have recently made changes to their positions in the company. Nisa Investment Advisors LLC bought a new stake in shares of NantKwest in the 2nd quarter worth approximately $100,000. Voya Investment Management LLC bought a new stake in shares of NantKwest in the 2nd quarter worth approximately $102,000. Gotham Asset Management LLC bought a new stake in shares of NantKwest in the 2nd quarter worth approximately $104,000. State of Wisconsin Investment Board bought a new stake in shares of NantKwest in the 2nd quarter worth approximately $129,000. Finally, Nationwide Fund Advisors lifted its holdings in shares of NantKwest by 67.6% in the 2nd quarter. Nationwide Fund Advisors now owns 17,302 shares of the biotechnology company’s stock worth $131,000 after acquiring an additional 6,977 shares during the last quarter. Hedge funds and other institutional investors own 18.82% of the company’s stock.
Receive News & Ratings for NantKwest Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantKwest Inc. and related companies with MarketBeat.com's FREE daily email newsletter.